Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The drug ...

Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway. APPULSE-PNH is a phase IIIB multicenter, single-arm, open-label study to evaluate the efficacy and safety of twice ...

including Novartis’ oral targeted factor B inhibitor Fabhalta (iptacopan) which was approved last December as the first oral monotherapy for adults with PNH. Another rival is Apellis’ C3 ...

Max to immediately begin process to provide humanitarian access for Fabhalta ® (iptacopan ... expand our reach to include people living with PNH in low-resource countries without access to ...

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved ...

The Scottish Medicines Consortium (SMC) approved the drugs for use by NHS Scotland.

Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is an oral, Factor B ...